Antivascular endothelial growth factor treatment in pseudoxanthoma elasticum patients.
The eye in patients with pseudoxanthoma elasticum, an autosomal recessive disease, shows several lesions, like peau d'orange, angioid streaks, comet lesions, and paired hyperpigmented smudges. The most devastating ocular complication is the development of choroidal neovascularizations (CNV). This exudative disease of the central retina leads to loss of visual acuity, and results of treatments in the past have been disappointing. From the present evidence it may be concluded that intravitreal antivascular endothelial growth factor (anti-VEGF) therapy with ranibizumab or bevacizumaab is beneficial for the treatment of CNV secondary to angioid streaks associated with PXE. Especially in the early stages of the disease, visual acuity can be maintained or even improved over a prolonged period of time, even with a low number of injections. Later in the course of the disease, when more widespread atrophic changes have occurred, the perspective is more bleak. Although there seem to be arguments to treat selected patients with a maintenance treatment of intravitreal injections once every 2 months, an as-needed regimen is the most used strategy. Patients need to be aware of the off-label nature of the treatment with anti-VEGF and also need to be informed about the possible increased risk of cardiovascular and/or thromboembolic events, although at present no definite proof has been documented of this higher risk in patients with or without PXE treated with intravitreal anti-VEGF. Overall, based on the evidence available, intravitreal treatment with anti-VEGF seems to be the best choice at present to treat patients with CNV secondary to angioid streaks and PXE.
Verbraak
Frank D
FD
Departments of Ophthalmology and Biomedical Engineering &amp; Physics, Academic Medical Center, Amsterdam, The Netherlands.
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000793:Angioid Streaks / Q000150:complications*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology* / Q000235:genetics* / Q000473:pathology; D005808:Genes, Recessive; D006801:Humans; D056965:Injections, Intraocular; D011561:Pseudoxanthoma Elasticum / Q000150:complications* / Q000235:genetics; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab